Journal List > J Korean Med Assoc > v.51(2) > 1041992

Park: Extensively Drug Resistant-Tuberculosis, XDR-TB

Abstract

Multidrug-resistant tuberculosis(MDR-TB), resistant to at least the two main TB drugsisoniazid and rifampicin, has been a threat to TB control because the treatment requires more toxic drugs and longer period with poor treatment outcomes. Recently, more serious concerns have been raised about extensively drug resistant-tuberculosis (XDR-TB), which shows resistance to fluoroquinolones and aminoglycosides in addition to isoniazid and rifampicin. XDR-TB is a serious global health threat because the cure is very difficult as few sensitive anti-TB drugs remain. XDR-TB develops when first-and second-line anti-TB drugs are misused during the course of treatment, most commonly due to poor compliance of the patients to the treatment regimen. People with XDR-TB can pass the XDR-TB bacteria to other people. Thus, every effort should be made to prevent the development of XDR-TB by establishing an effective TB control program maximizing patient adherence to prescribed anti-TB regimen and minimizing contact of XDR-TB patients with other people to prevent the spread of XDR-TB.

Figures and Tables

Table 1
Number and percentage of XDR-TB cases by geographic region and years-worldwide, 2000~2004
jkma-51-168-i001

*Australia, Belgium, Canada, France, Germany, Ireland, Japan, Portugal, Spain, United Kingdom, United States

References

1. Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest. 2006. 130:261–262.
2. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR. 2006. 55:1176.
3. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007. 45:1409–1414.
crossref
4. Helen SC, Stobdan K, Sholpan A, Vinciane S, Zinaida NT, Sabine RG, Hamraev AK, Yared K, Clair M. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan Uzbekistan: Treatment complexity and XDR-TB among treatment failure. PLos One. 2007. 2:e1126.
5. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR. 2007. 56:250–253.
6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR. 2006. 55:301–305.
7. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Frienland G. Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006. 368:1575–1580.
crossref
8. Singh S, Sankar MM, Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS. 2007. 21:2345–2347.
crossref
9. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug resistant tuberculosis. Clin Infect Dis. 2007. 45:1290–1295.
crossref
10. Lee JY, Choi HJ, Lee HY, Joung EY, Huh JW, Oh YM, Lee SD, Kim DS, Kim WD, Shim TS. Recovery rate and characteristics of nontuberculous mycobacterial isolates in a university hospital in Korea. Tuber Respir Dis. 2005. 58:385–391.
crossref
11. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Javashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007. 51:576–582.
crossref
12. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Cehmother. 2005. 56:180–185.
crossref
13. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003. 47:1824–1831.
crossref
14. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med. 2001. 162:1055–1058.
15. Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet. 2006. 367:945–947.
crossref
16. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglilon M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther. 2007. 5:857–871.
crossref
17. Kim HJ. Current situation of tuberculosis and its control in Korea. J Korean Med Assoc. 2006. 49:762–772.
crossref
TOOLS
Similar articles